Sugi Predict

Sugi Predict / Compounds / SCHEMBL2938437

SCHEMBL2938437

SCHEMBL2938437

CC1C(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C(=O)N1C(NC(=O)Cc1ccccc1)c1ccncc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.47
▸ CNR2 P34972 2/20 0.36
▸ SIGMAR1 Q99720 2/20 0.35
▸ RORC P51449 4/20 0.34
▸ PTGDR2 Q9Y5Y4 1/20 0.34
▸ RORA P35398 1/20 0.34
▸ SMO Q99835 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ MDM2 Q00987 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ ELANE P08246 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2937621 0.87 LIPE (0.42) CNR2SIGMAR1
SCHEMBL3724496 0.86 IGF1R (0.41) IGF1RCNR2SIGMAR1SMO
SCHEMBL2938325 0.83 IGF1R (0.40) IGF1RALDH1A1KDM4E
SCHEMBL2937249 0.83 IGF1R (0.47) IGF1RCNR2RORCPTGDR2RORA
SCHEMBL2940492 0.83 IGF1R (0.42) IGF1RMDM2
SCHEMBL2939364 0.82 CNR2 (0.39) IGF1RCNR2SIGMAR1RORCPTGDR2
SCHEMBL6176591 0.75 IGF1R (0.40) IGF1RCNR2RORCRORAGAA
SCHEMBL2940490 0.75 IGF1R (0.61) IGF1RSMOGAAMAPTNAMPT
SCHEMBL6174459 0.73 IGF1R (0.38) IGF1RGAAMAPTLMNAALDH1A1
Trifluoroacetic Acid SCHEMBL2940273 0.72 IGF1R (0.58) IGF1RPTGDR2SMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885CNR2 3922/4885SIGMAR1 3262/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885CNR2 3140/4885SIGMAR1 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.